Surgery in Non–Small-Cell Lung Cancer

Article

Surgical management of the patient with non–small-cell lung cancer (NSCLC) is complex. When should stereotactic body radiation therapy be used? What are the advantages of video-assisted thoracic surgery? Test your knowledge in our latest quiz.

Surgical management of the patient with non–small-cell lung cancer (NSCLC) is complex. When should stereotactic body radiation therapy be used? What are the advantages of video-assisted thoracic surgery? Test your knowledge in our latest quiz.

Question 1

Answer and Question 2 on Next Page »

Answer

B.

Surgery in patients with one N2 lymph node station involved by a lymph node smaller than 3 cm.

This practice pattern was selected by 90.5% of the member institutions, according to the NCCN. In addition, 80% said they would use endobronchial ultrasound with or without endoscopic ultrasound in initial evaluation of the mediastinum, and 40.5% noted they would use pathologic evaluation of the mediastinum, after neoadjuvant therapy, to make a final decision before surgery.

Question 2

Answer and Question 3 on Next Page »

Answer

C.

5 cm

The guidelines note that such patients should be counseled about the subsequent risk of locoregional and distant failure.

Question 3

Answer and Question 4 on Next Page »

Answer

C.

Race

The study found that half of patients alive at 5 years were alive at 10 years, with 10-year survival “associated with younger age, earlier stage, non-squamous histology, lobectomy, and fewer comorbidities, but not race.”

Question 4

Answer and Question 5 on Next Page »

Answer

B.

True

The study compared overall survival and lung cancer–specific survival among patients after lobectomy, segmentectomy, or wedge resection.

Question 5

Answer on Next Page »

Answer

D.

All of the above

VATS is also associated with a shorter length of hospitalization, minimal locoregional recurrence, and improved discharge independence in older and high-risk patients, according to the guidelines.

Recent Videos
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
3 experts in this video
Related Content